Navigation Links
American Stroke Association Late-Breaking Science Report: Antiplatelet Drug May Be Better Than Aspirin in Preventing Recurrent Strokes
Date:2/26/2010

Study highlights:

-- The antiplatelet drug cilostazol was better than aspirin in preventing a recurrent stroke in a Japanese trial.

-- Compared to patients taking aspirin, patients taking the drug were less likely to have new ischemic stroke or develop bleeding requiring hospitalization.

-- Cilostazol is used to reduce leg pain associated with peripheral vascular disease in the United States.

SAN ANTONIO, Feb. 26 /PRNewswire-USNewswire/ -- The antiplatelet drug cilostazol — used in the United States to treat leg pain associated with peripheral vascular disease — was more effective and safer than aspirin at  preventing recurrent strokes in a Japanese trial presented as late-breaking science at the American Stroke Association's International Stroke Conference 2010.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100222/AHSALOGO)

"This study demonstrated for the first time that cilostazol significantly reduces the risk of recurrent ischemic [blood-clot caused] stroke and the incidence of serious cerebral hemorrhage, compared to aspirin," said Yukito Shinohara, M.D., lead author of the study and head of neurology at Tachikawa Hospital in Tokyo, Japan.

Antiplatelet drugs interfere with the blood's ability to clot.

In the randomized, double-blind study of nearly 2,700 stroke patients with non-cardioembolic ischemic stroke (stroke not caused by blood clots originating in the heart), those treated with cilostazol were 25.7 percent less likely to suffer a stroke than those who received aspirin.

Among the study's other findings:

  • Strokes occurred in 82 of the 1,337 cilostazol-treated patients (two strokes were fatal), during 2,965.9 person-years.  The 1,335-patient aspirin group suffered 119 strokes, including three deaths, over 3,203.6 person-years.  Person-years is the total time all patients in a group received their assigned drug.
  • A hemorrhagic stroke or hemorrhage that required hospitalization occurred in 23 patients taking cilostazol and 57 of those receiving aspirin — a significant difference.

"The primary implication of this trial is that the risk of recurrence of stroke in patients can be reduced without increasing the incidence of hemorrhage by oral administration of cilostazol," Shinohara said.  

Cilostazol is approved in the United States only for reducing intermittent claudication, pain caused by an inadequate flow of blood to the leg muscles that's common with peripheral vascular disease.  In Japan, the drug is recommended and widely used for preventing recurrence of ischemic stroke.

Shinohara and colleagues sought to determine whether cilostazol's preventive powers were in the same range as — or superior to — the effects of aspirin.

The researchers analyzed results from 2,681 ischemic stroke patients treated in 278 Japanese institutions between December 2003 and October 2006.  Patients were followed through 2008. All patients had suffered non-cardioembolic ischemic stroke within 26 weeks prior to enrollment and their symptoms had remained stable.  They were randomized to receive either 100 mg of cilostazol twice daily or 81 mg of aspirin once daily.

"During the trial, we noted that the incidence of recurrent stroke was very low," Shinohara said. "We did not expect that there would be differences between the recurrence rate of stroke in the cilostazol and aspirin groups."

Co-authors are Takenori Yamaguchi, M.D.; Yasuo Katayama, M.D.; Shinichiro Uchiyama, M.D.; Katsuya Nishimaru, M.D.; Yasuhisa Kitagawa, M.D.; Hideo Kusuoka, M.D.; Chokoh Genka, M.D., ; Motoo Tsushima, M.D.; Hiroko Yamamoto, M.D.; Norio Tanahashi, M.D.; Shunnosuke Handa, M.D.; Kempei Matsuoka, M.D.; Yasuo Ohashi, Ph.D.; Yukihiro Koretsune, M.D.; Tohru Sawada, M.D.; and Chikuma Hamada, Ph.D.

Author disclosures are on the abstract.

Otsuka Pharmaceutical Co., Ltd, the maker of cilostazol, funded the study.

Click here to view the video interview with Yukito Shinohara, M.D.

Statements and conclusions of study authors that are presented at American Heart Association/American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.  The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing science content.  Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

Note: Actual presentation time is noon CT.

SOURCE American Stroke Association

Back to top
'/>"/>
SOURCE American Stroke Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Heart Association/American College of Cardiology Joint Science Advisory: AHA/ACC Issue Advisory on Diabetes Drugs and Heart Risk
2. Americans Living Longer, Healthier Lives Due to Medical Innovation and New Therapies
3. Many Americans Enjoying Longer, Healthier Lives Due to Medical Innovation and New Therapies
4. American Heart Association Rapid Access Journal Report: Implanted Monitor Accurately Detects Heart Rhythm Disturbances
5. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today
6. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Michigan Today
7. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Massachusetts Today
8. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in North Carolina Today
9. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Missouri Today
10. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Pennsylvania Today
11. The American Academy of Pain Medicine Announces this Years Presidential Commendations and Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)... 13, 2017   OrthoAtlanta has been named the ... Host Committee (AFHC) for the 2018 College Football Playoff (CFP) ... at Mercedes-Benz Stadium in Atlanta, Georgia . ... "I,m In" campaign, participating in many activities leading up to, ... ...
(Date:9/12/2017)... N.J. , Sept. 12, 2017  Consumer reviews on the ... Hearing as the number one company for hearing aids, ranking ... and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high ...
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... “Fruit of the Spirit: ... while exploring nature that God has created. “Fruit of the Spirit: “Love”” is the ... now a devoted wife and mother of five. Halimah is an avid writer, her ...
(Date:9/22/2017)... Encino, CA (PRWEB) , ... September 22, 2017 ... ... ways to preserve fertility and create life. Although frozen embryos have a slight ... circumstances. , “Egg freezing is a wonderful opportunity for women undergoing medical ...
(Date:9/21/2017)... Naples, FL (PRWEB) , ... September 21, 2017 , ... ... , Aesthetic Surgery Center in Naples, Florida is pleased to announce that Plastic Surgeon ... Business Top 40 Under 40 is an annual award that was started ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Infinity Behavioral Health Services for professionals in the addiction treatment industry entitled: ... . , Insurance companies and state and federal governments are increasingly scrutinizing ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... communities, nine governmental public health departments have been awarded five-year accreditation status through ... that the benefits of being served by a PHAB-accredited health department now ...
Breaking Medicine News(10 mins):